{
    "nct_id": "NCT05048797",
    "official_title": "An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)",
    "inclusion_criteria": "* Participants at least 18 years of age\n* Locally advanced and unresectable NSCLC, not amenable to curative therapy, or metastatic disease\n* Histologically documented non-squamous NSCLC with HER2 mutation in exons 19 or 20 by tissue NGS or ctDNA\n* Treatment-naïve for palliative intent systemic therapy for locally advanced or metastatic disease\n* Left ventricular ejection fraction (LVEF) ≥ 50%\n* Measurable disease assessed by Investigator based on RECIST 1.1\n* Protocol-defined adequate organ function including cardiac, renal, hepatic function\n* ECOG 0-1\n* Having tumour tissue available for central testing\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 123 Years",
    "exclusion_criteria": "* Tumors with targetable alterations to EGFR (or other targetable mutations including but not limited to ALK, if routinely tested as a targetable alteration with approved available therapy)\n* Any untreated brain metastases, including asymptomatic or clinically inactive brain metastases\n* Active autoimmune or inflammatory disorders\n* Medical history of myocardial infarction within 6 months prior to randomization\n* History of non-infectious pneumonitis/ILD, current or suspected ILD\n* Lung-specific intercurrent clinical significant severe illness\n* Contraindication to platinum-based doublet chemotherapy or pembrolizumab",
    "miscellaneous_criteria": ""
}